Autopsy report · NCT00914069

Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter

“Funding Stopped”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 2 months before it stopped.
• 175 participants enrolled.
• Results were posted on the registry 3 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

C. R. Bard

Sponsor type

Industry

Conditions

Vascular Access Complication

Interventions

RIVS vascular access; Conventional vascular access

Participants

175

Sites

3

Countries

United States

Trials that died the same way

• Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH
  “Funding was stopped” (98% match in meaning)
• Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
  “Funding ceased” (94% match in meaning)
• SPOON: Sustained Program for Improving Nutrition - Mexico
  “Funding cancelled” (89% match in meaning)
• Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy
  “no longer had funding to continue” (88% match in meaning)
• Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG
  “Funding ended” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.